Item 7.01. Regulation FD Disclosure.

On December 8, 2022, Context Therapeutics Inc. ("Context") issued a press release announcing preliminary Phase 2 data from the ongoing SMILE trial of onapristone extended release (ONA-XR), Context's novel, first-in-class, potent, orally administered progesterone receptor (PR) antagonist, in metastatic breast cancer. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

The information in this Item 7.01 and Exhibit 99.1 attached hereto are being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing.

Item 8.01. Other Events.

On December 7, 2022, data was presented at the 2022 San Antonio Breast Cancer Symposium® (SABCS®) noting preliminary Phase 2 findings of the SMILE trial, highlighting a 4-month progression free survival (PFS) rate of 44%, and favorable safety and tolerability.




Item 9.01. Exhibits.

(d) Exhibits

Exhibit No.              Description
                           Press Release issued by Context Therapeutics Inc., dated
99.1                     December 8, 2022
                         Cover Page Interactive Data File (embedded within the inline
104                      XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses